After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products

 
• By Derrick Gingery
ReviewStamp_1200x675
The expedited assessment that COVID-19 product applications are receiving could become permanent FDA practice, along with some remote clinical trial monitoring practices. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards